Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | MMP9 | P14780 | 2/20 | 0.34 |
| ▸ | MMP8 | P22894 | 2/20 | 0.34 |
| ▸ | MMP13 | P45452 | 2/20 | 0.34 |
| ▸ | QPCT | Q16769 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL236739 | 1.00 | MMP2 (0.34) | MMP2MMP9MMP8MMP13QPCT | |
| SCHEMBL235769 | 0.86 | MMP2 (0.34) | MMP2MMP9MMP8MMP13ALDH1A1 | |
| SCHEMBL235768 | 0.86 | MMP2 (0.34) | MMP2MMP9MMP8MMP13ALDH1A1 | |
| Nitenpyram SCHEMBL31030931 | 0.86 | SMN1; SMN2 (0.40) | ALDH1A1 | |
| Nitenpyram SCHEMBL25788 | 0.86 | SMN1; SMN2 (0.40) | ALDH1A1 | |
| Nitenpyram SCHEMBL13448342 | 0.86 | SMN1; SMN2 (0.40) | ALDH1A1 | |
| Nitenpyram SCHEMBL29388004 | 0.86 | SMN1; SMN2 (0.40) | ALDH1A1 | |
| SCHEMBL238070 | 0.86 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL238069 | 0.86 | ALDH1A1 (0.31) | ALDH1A1 | |
| Nitenpyram SCHEMBL25789 | 0.86 | SMN1; SMN2 (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225940-B1 | Oil dispersions of nAChR binding neonicotinoids | GAT MICROENCAPSULATION GMBH (AT) | 2014-03-12 | — | — | EP | disclosed |
| US-8293733-B2 | Oil dispersions of nAChR binding neonicotinoids | GAT MICROENCAPSULATION AG (AT) | 2012-10-23 | — | — | US | disclosed |
| US-20120004104-A1 | OIL DISPERSIONS OF nAChR BINDING NEONICOTINOIDS | GAT MICROENCAPSULATION AG (AT) | 2012-01-05 | — | — | US | disclosed |
| EP-2225940-A1 | Oil dispersions of nAChR binding neonicotinoids | GAT Microencapsulation AG (AT) | 2010-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004104-A1 | OIL DISPERSIONS OF nAChR BINDING NEONICOTINOIDS | CHRND, ITGAM, CHRM2 | MMP2 3468/4885MMP9 2860/4885MMP8 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.